JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Nvidia Develops New Location-Verification Technology for AI Chips 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
NEW YORK, May 04, 2018 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 8, 2018 at 8:30am ET to discuss results for the first quarter of 2018 and provide a business outlook for the remainder of the year. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2018 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. An audio recording of the conference call will also be available for replay on the Company’s website, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
CONTACT:
Jenna Bosco
SVP, Corporate Communications
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]
